Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock
Dyne Therapeutics (NASDAQ: DYN), a clinical-stage company specializing in genetically driven neuromuscular diseases, has announced the pricing of a public offering of 24,242,425 shares of its common stock at $8.25 per share. The offering is expected to generate gross proceeds of $200.0 million before deducting underwriting discounts and commissions.
The company has granted underwriters a 30-day option to purchase up to an additional 3,636,363 shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close around July 2, 2025. Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities are serving as joint book-running managers, with Jones acting as co-manager.
[ "Expected gross proceeds of $200.0 million to strengthen company's financial position", "Additional potential proceeds through 30-day option for underwriters to purchase extra shares", "Strong institutional backing with multiple prominent investment banks as joint book-running managers" ]Dyne Therapeutics (NASDAQ: DYN), una societ脿 in fase clinica specializzata in malattie neuromuscolari di origine genetica, ha annunciato il prezzo di un offerta pubblica di 24.242.425 azioni del suo capitale ordinario a 8,25 dollari per azione. L'offerta dovrebbe generare proventi lordi per 200,0 milioni di dollari prima di detrarre sconti e commissioni di sottoscrizione.
La societ脿 ha concesso agli underwriter un'opzione di 30 giorni per acquistare fino a un massimo di 3.636.363 azioni aggiuntive al prezzo dell'offerta pubblica, al netto degli sconti e delle commissioni di sottoscrizione. La chiusura dell'offerta 猫 prevista intorno al 2 luglio 2025. Morgan Stanley, Jefferies, Stifel e Guggenheim Securities agiscono come joint book-running manager, con Jones come co-manager.
- Proventi lordi attesi di 200,0 milioni di dollari per rafforzare la posizione finanziaria della societ脿
- Possibili proventi aggiuntivi grazie all'opzione di 30 giorni per gli underwriter di acquistare ulteriori azioni
- Solido supporto istituzionale con diverse importanti banche d'investimento come joint book-running manager
Dyne Therapeutics (NASDAQ: DYN), una empresa en etapa cl铆nica especializada en enfermedades neuromusculares gen茅ticamente determinadas, ha anunciado el precio de una oferta p煤blica de 24,242,425 acciones de sus acciones ordinarias a $8.25 por acci贸n. Se espera que la oferta genere ingresos brutos de $200.0 millones antes de deducir descuentos y comisiones de suscripci贸n.
La compa帽铆a ha otorgado a los suscriptores una opci贸n de 30 d铆as para comprar hasta 3,636,363 acciones adicionales al precio de la oferta p煤blica, menos descuentos y comisiones de suscripci贸n. Se espera que la oferta cierre alrededor del 2 de julio de 2025. Morgan Stanley, Jefferies, Stifel y Guggenheim Securities act煤an como gestores conjuntos principales, con Jones como co-gestor.
- Ingresos brutos esperados de $200.0 millones para fortalecer la posici贸n financiera de la compa帽铆a
- Potenciales ingresos adicionales a trav茅s de una opci贸n de 30 d铆as para que los suscriptores compren acciones extra
- Fuerte respaldo institucional con m煤ltiples bancos de inversi贸n prominentes como gestores conjuntos principales
Dyne Therapeutics (NASDAQ: DYN)電� 鞙犾爠靹� 鞁犼步攴检湣 歆堩櫂鞚� 鞝勲鞙茧 頃橂姅 鞛勳儊 雼硠 旮办梾鞙茧, 氤错喌欤� 24,242,425欤�毳� 欤茧嫻 8.25雼煬鞐� 瓿店皽 氚滍枆頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 鞚措矆 瓿惦搿� 2鞏� 雼煬鞚� 齑� 靾橃澋鞚� 鞓堨儊霅橂┌, 鞚胳垬 頃犾澑 氚� 靾橃垬耄� 瓿奠牅 鞝� 旮堨暋鞛呺媹雼�.
須岇偓電� 鞚胳垬鞚胳棎瓴� 30鞚� 霃欖晥 於旉皜搿� 3,636,363欤�毳� 瓿惦臧�鞐� 鞚胳垬頃� 靾� 鞛堧姅 鞓奠厴鞚� 攵�鞐枅鞀惦媹雼�. 瓿惦 毵堦皭鞚� 2025雲� 7鞗� 2鞚缄步鞙茧 鞓堨儊霅╇媹雼�. Morgan Stanley, Jefferies, Stifel, Guggenheim Securities臧� 瓿惦彊 欤缄皠靷 彀胳棳頃橂┌, Jones臧� 瓿惦彊 毵る媹鞝�搿� 頇滊彊頃╇媹雼�.
- 2鞏� 雼煬鞚� 齑� 靾橃澋 鞓堨儊鞙茧 須岇偓鞚� 鞛 靸來儨 臧曧檾
- 鞚胳垬鞚胳棎瓴� 30鞚� 鞓奠厴鞚� 韱淀暅 於旉皜 欤检嫕 毵れ瀰鞙茧 鞛犾灛鞝� 於旉皜 靾橃澋 頇曤炒
- 鞐煬 欤检殧 韴瀽鞚�頄夓澊 瓿惦彊 欤缄皠靷 彀胳棳頃橃棳 臧曤牓頃� 旮瓣磤 歆�鞗�
Dyne Therapeutics (NASDAQ : DYN), une soci茅t茅 en phase clinique sp茅cialis茅e dans les maladies neuromusculaires g茅n茅tiquement d茅termin茅es, a annonc茅 le prix d鈥檜ne offre publique de 24 242 425 actions de ses actions ordinaires 脿 8,25 $ par action. L鈥檕ffre devrait g茅n茅rer des produits bruts de 200,0 millions de dollars avant d茅duction des rabais et commissions de souscription.
La soci茅t茅 a accord茅 aux souscripteurs une option de 30 jours pour acheter jusqu鈥櫭� 3 636 363 actions suppl茅mentaires au prix de l鈥檕ffre publique, moins les rabais et commissions de souscription. La cl么ture de l鈥檕ffre est pr茅vue aux alentours du 2 juillet 2025. Morgan Stanley, Jefferies, Stifel et Guggenheim Securities agissent en tant que gestionnaires principaux conjoints, avec Jones en co-gestionnaire.
- Produits bruts attendus de 200,0 millions de dollars pour renforcer la position financi猫re de la soci茅t茅
- Recettes suppl茅mentaires potentielles gr芒ce 脿 l鈥檕ption de 30 jours accord茅e aux souscripteurs pour acheter des actions suppl茅mentaires
- Soutien institutionnel solide avec plusieurs grandes banques d鈥檌nvestissement en tant que gestionnaires principaux conjoints
Dyne Therapeutics (NASDAQ: DYN), ein klinisch fortgeschrittenes Unternehmen, das sich auf genetisch bedingte neuromuskul盲re Erkrankungen spezialisiert hat, hat die Preisfestsetzung f眉r ein 枚ffentliches Angebot von 24.242.425 Aktien seiner Stammaktien zu 8,25 USD pro Aktie bekannt gegeben. Das Angebot soll vor Abzug von Underwriting-Rabatten und Provisionen Bruttoerl枚se von 200,0 Millionen USD erzielen.
Das Unternehmen hat den Underwritern eine 30-t盲gige Option einger盲umt, bis zu 3.636.363 zus盲tzliche Aktien zum 枚ffentlichen Angebotspreis abz眉glich Underwriting-Rabatten und Provisionen zu kaufen. Der Abschluss des Angebots wird f眉r etwa den 2. Juli 2025 erwartet. Morgan Stanley, Jefferies, Stifel und Guggenheim Securities fungieren als gemeinsame Bookrunner, wobei Jones als Co-Manager t盲tig ist.
- Erwartete Bruttoerl枚se von 200,0 Millionen USD zur St盲rkung der finanziellen Position des Unternehmens
- Zus盲tzliche potenzielle Erl枚se durch 30-t盲gige Option f眉r Underwriter zum Kauf weiterer Aktien
- Starke institutionelle Unterst眉tzung durch mehrere namhafte Investmentbanken als gemeinsame Bookrunner
- None.
- Significant dilution for existing shareholders with 24.2 million new shares being issued
- Additional potential dilution if underwriters exercise their option for 3.6 million more shares
Insights
Dyne's $200M stock offering strengthens cash position for clinical programs in neuromuscular diseases but dilutes existing shareholders by ~13%.
Dyne Therapeutics has priced a
The
For clinical-stage biotechs without approved products, strategic capital raises are critical to fund R&D and clinical trials through to data readouts. This
WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics,聽Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an underwritten public offering of 24,242,425 shares of its common stock at a public offering price of
Morgan Stanley, Jefferies, Stifel and Guggenheim Securities are acting as joint book-running managers for the offering. Jones is acting as co-manager for the offering.
The offering is being made pursuant to a shelf registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission (鈥淪EC鈥�) on March 5, 2024 and became automatically effective upon filing. This offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and may be obtained for free by visiting the SEC鈥檚 website at www.sec.gov. A final prospectus supplement relating to the offering will be filed with the SEC. When available, copies of the final prospectus supplement and the accompanying prospectus may also be obtained by contacting: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at [email protected]; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at [email protected]; Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at [email protected]; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at [email protected]. 聽聽
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Dyne Therapeutics
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease.
Forward-Looking Statements聽聽
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements relating to the anticipated closing date of the public offering, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words 鈥渁nticipate,鈥� 鈥渂elieve,鈥� 鈥渃ontinue,鈥� 鈥渃ould,鈥� 鈥渆stimate,鈥澛犫�渆xpect,鈥� 鈥渋ntend,鈥� 鈥渕ay,鈥� 鈥渕ight,鈥� 鈥渙bjective,鈥� 鈥渙ngoing,鈥� 鈥減lan,鈥� 鈥減redict,鈥� 鈥減roject,鈥� 鈥減otential,鈥� 鈥渟hould,鈥� or 鈥渨ould,鈥� or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including the risks and uncertainties related to the satisfaction of customary closing conditions for the public offering and other factors discussed in the 鈥淩isk Factors鈥� section of the preliminary prospectus supplement filed with the SEC on June 30, 2025, as well as the risks and uncertainties identified in Dyne鈥檚 filings with the SEC, including Dyne鈥檚 most recent Form 10-Q and in subsequent filings Dyne may make with the SEC. In addition, the forward-looking statements included in this press release represent Dyne鈥檚 views as of the date of this press release. Dyne anticipates that subsequent events and developments will cause its views to change. However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne鈥檚 views as of any date subsequent to the date of this press release.
Contacts:
Investors
Mia Tobias
[email protected]
781-317-0353
Media
Stacy Nartker
[email protected]
781-317-1938
FAQ
What is the size and price of Dyne Therapeutics' (DYN) public offering in 2025?
When will Dyne Therapeutics' (DYN) 2025 public offering close?
Who are the underwriters for Dyne Therapeutics' (DYN) 2025 public offering?
What additional options do the underwriters have in DYN's 2025 offering?
What is Dyne Therapeutics' (DYN) business focus?
